Navigation Links
AMDL Reaffirms 2008 Guidance and Provides Additional Information
Date:9/15/2008

TUSTIN, Calif., Sept. 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with major operations in China and the US, announced today it is reaffirming guidance for Q3 and FY2008. Additionally, the Company is providing information for the benefit of stockholders in response to the heightened activity in its common stock on the American Stock Exchange (AMEX) in recent days.

While it is the Company's normal policy to not comment on unusual trading activity or changes in the Company's quoted stock price or to provide updated guidance between quarterly conference calls, the Company has recently received numerous inquiries requesting updated guidance in light of recent developments in general market conditions and the China and US pharmaceutical sector.

In response to specific inquiries from stockholders, AMDL is reiterating previously issued guidance and providing additional information as follows:

-- The Company has stated anticipated net sales of $13 million for the third quarter 2008. The Company believes it will achieve this primarily through continued distribution and sales for its top-selling products in China, which have shown consistent returns for the last 8 quarters.

-- The Company reaffirms it is on track to achieve its paramount goal for 2008, which is to once again achieve record annual earnings in 2008 with a 100% increase in sales over 2007. For FY2008 AMDL has targeted net sales ranging between $30 to $38.7 million with gross margins of 46% to 52% -- a 100% increase over the same period in 2007 where the Company achieved gross revenues of $15 million with a gross margin of 54%..

-- Potential revenues for AMDL's ELISA DR-70(R) (FDP) in vitro diagnostic (IVD) test which was approved the US FDA on July 3, 2008 for the monitoring of colorectal cancer are not included in AMDL's 2008 guidance forecast. The Company has presented DR-70 technology to both US and International diagnostic manufacturing companies and national reference laboratories with the goal of securing strategic partnerships to market and sell the product globally. According to US-based medical research group Kalorama Research, the world market for IVD tests for cancer is growing at nearly 11% annually and could reach nearly $8 billion by the end of 2012. (Kalorama Research Group: 2008)

Since issuance of the Company's news release on August 1, 2008 announcing the Company's updated guidance for Q2 and FY2008, the Company has not disclosed any material new information or altered such guidance and he Company has no known or material reasons as to why the stock is currently trading down. AMDL's operations are running business as usual and in-line with its 2008 operating plan. On August 15, 2008 the Company announced its second quarter 2008 results, stating AMDL posted $5.8 million in sales with a revenue increase of 140%. Stockholders and other interested parties are encouraged to view to the Company's Q2 conference call script which is available on the AMDL website http://www.amdl.com.

According to AMDL President and CEO Gary Dreher, "In light of the increasingly challenging financial markets, we are successfully managing our business to plan with product sales in China aligned to our 2008 guidance forecasts. We view AMDL continue to view AMDL as a winning and undervalued proposition for shareholders and will remain focused on delivering consistent positive results to the market."

The Company plans to report third quarter earnings in November 2008 and expects to conduct a conference call to review the quarterly results and information at that time. A subsequent press release will be issued announcing the date of the conference call and call-in details. For additional information contact AMDL Investor Relations at kszarkowitz@amdl.com.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

IR Contact

Kristine Szarkowitz,

206.310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Grocery Manufacturers Association: FDA Once Again Reaffirms Safety of Bisphenol A (BPA) for All Consumers
2. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
3. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
4. Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook
5. Grocery Manufacturers Association: Canadian Risk Assessment Reaffirms Safety of Bisphenol A (BPA) for Adults and Children
6. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
7. Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
10. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
11. New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: